Real-World Evidence Influencing Academic-Setting Decisions About Radioligand Treatment Timing

In the fourth segment of their roundtable discussion, the panel turns to exploring how recent clinical trials, including the VISION and PSMAfore studies, are shaping the treatment landscape for advanced prostate cancer. They cover the potential of radioligands in both pre- and post-chemotherapy settings, and the role of patient preferences in clinical decision-making.

View the fifth part of this series: Recent Trials of Interest, Barriers to Radioligand Therapy, and Nuances in PSMA Engagement